Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 9/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 9/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6346049 | 0.90 | RAB9A (0.57) | RAB9ANPC1ITGB3ITGA2BITGB1 | |
| SCHEMBL6354954 | 0.90 | NPC1 (0.49) | RAB9ANPC1ITGB3ITGA2BITGB1 | |
| SCHEMBL6782622 | 0.86 | NPC1 (0.47) | RAB9ANPC1ITGB3ITGA2BITGB1 | |
| SCHEMBL6343632 | 0.84 | ITGB1 (0.60) | ITGB3ITGA2BITGB1ITGA4SMN1; SMN2 | |
| SCHEMBL6343091 | 0.83 | ITGB1 (0.58) | ITGB1ITGA4 | |
| SCHEMBL3141465 | 0.82 | NPC1 (0.50) | RAB9ANPC1ITGB3ITGB1ITGA4 | |
| SCHEMBL6346248 | 0.81 | RAB9A (0.56) | RAB9ANPC1ITGB3ITGA2BITGB1 | |
| SCHEMBL6344910 | 0.80 | ITGB1 (0.57) | ITGB1ITGA4 | |
| SCHEMBL7462011 | 0.79 | KMT2A (0.47) | RAB9AITGB3ITGA2BITGB1ITGA4 | |
| SCHEMBL7472953 | 0.79 | ITGB1 (0.51) | RAB9ANPC1ITGB3ITGA2BITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949534-B2 | Cell adhesion inhibitors | BIOGEN IDEC MA INC. (US) | 2005-09-27 | — | — | US | claimed |
| US-20040053907-A1 | Cell adhesion inhibitors | BIOGEN, INC. A MASSACHUSETTS CORPORATION. | 2004-03-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053907-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | RAB9A 1779/4885NPC1 2649/4885ITGB3 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.